| abstract |
BINDER / ACTIVE AGENT CONJUGATES TARGETED AGAINST CXCR5, HAVING ENZYMATICALLY CLIVABLE BINDERS AND IMPROVED ACTIVITY PROFILE.nThe invention relates to an innovative ligand-drug conjugate with improved properties, to activate metabolites of said ADCs and processes for the preparation thereof. The invention particularly relates to antibody-drug conjugates (ADCs) with selected CXCR5 antibodies and KSP inhibitors. The present invention also relates to the use of said conjugates for the treatment and / or prevention of diseases and the use of said conjugates for the production of drugs for the treatment and / or prevention of diseases, in particular, hyperproliferative and / or diseases. or angiogenic, such as cancer diseases. |